Synthesis of Some Novel Chromenopyrimidine Derivatives and Evaluation of Their Biological Activities

authors:

avatar Akbar Mobinikhaledi a , * , avatar Naser Foroughifar b , avatar Tahere Mosleh a , avatar Ahmad Hamta c

Department of Chemistry, Faculty of Science, Arak University, Arak 38156-8-8349, Iran.
Faculty of Chemistry, Tehran North Branch, Islamic Azad University, Tehran, Iran.
Department of Biology, Arak University, Arak 38156-8-8349, Iran.
Iranian Journal of Pharmaceutical Research : IJPR: Vol.13, issue 3; 873-879
article type: Original Article
received: January , 2013
accepted: April , 2013
DOI: https://doi.org/10.22037/ijpr.2014.1539

how to cite: Mobinikhaledi A, Foroughifar N, Mosleh T, Hamta A. Synthesis of Some Novel Chromenopyrimidine Derivatives and Evaluation of Their Biological Activities. Iran J Pharm Res. 2014;13(3):e125481. https://doi.org/10.22037/ijpr.2014.1539.

Abstract

Pyrimidine nucleosides are constituents of fundamental structure of the cells. There has been considerable attentions in the chemistry of pyrimidine derivatives due to having a wide range of biological activities such as antiviral, anti-malarial agents, cytostatic, antithelemintic, antibacterial, adenosine receptor ligands, anti-cancer agents, compounds targeting delayed-type hypersensivity and anti-convulsant agents. As a part of our research work in the synthesis of pyrimidines containing biological activities, a series of chromenopyrimidine derivatives were synthesized by reaction of an intermediate imine and ammonia derivatives in good to high yields. All synthesized compounds were characterized using IR and NMR (1H and 13C) spectroscopy and elemental analysis data. The antibacterial activity of these compounds was investigated against Staphylococcus aureus (RTCC, 1885), and Escherichia Coli (ATCC, 35922).

Introduction

Pyrimidine is a basic nucleus in DNA and RNA and plays an essential role in chemistry and biological systems (1). Pyrimidine derivatives have received considerable attentions due to their diverse range of therapeutic and pharmacological properties as antiviral (2), cytostatic (3-5), immunomodulating and antibacterial (6-9). Fused heterocyclic pyrimidines have also shown a wide range of biological activities, such as antitumor, antiviral, antimicrobial, antibacterial and anti-inflammatory (10-17). Study of various substituted pyrimidine derivatives indicated a good correlation between compound structures and antibacterial activity (18-24). Several methods have been reported for the synthesis of simple pyrimidine derivatives (1, 25-28). However, because of the incessant interest in this field, new efficient synthesis of some fused pyrimidine derivatives is still an important objective for synthetic organic chemists in order to find compounds with different biological activities.

In view of these reports and also due to continuation of our interests on synthesis of pyrimidines (29-32), we wish to report synthesis of some fused pyrimidine derivatives.

Experimental

Materials

All reagents and solvents used are commercially available. Reactions were monitored by thin layer chromatography (TLC) using silica gel F254 aluminum sheets (Merck). Melting points were measured on an Electrothermal apparatus. Infra-red spectra were recorded (KBr discs) with a Galaxy Series FT-IR 5000 spectrometer. The 1H NMR and 13C NMR spectra were recorded with a Bruker Avance 300 MHz spectrometer with DMSO-d6 and CDCl3 as the solvent and tetramethylsilane as an internal standard. Microanalyses were performed by the Elemental Analyzer (Elemental, Vario EL III) at the Arak University. The microbial strains are identified strains and were obtained from the Pasteur Institute of Iran. The bacterial strains studied are Staphylococcus aureus (RTCC, 1885), and Escherichia Coli (ATCC, 35922).

General procedure for the synthesis of compounds 6-8

In a typical experimental procedure (34-36), benzaldehyde 1 (1 mmol), malononitrile 2 (1 mmol), dimedone 3, resorcinol 4 or 2-naphthol 5 (1 mmol) were mixed in solvent and triethylamine (2-3 drops) as a catalyst was added. The reaction mixture was refluxed for 2-4 h. After the completion of the reaction, it was filtered and recrystallized from ethanol to afford the pure product 6-8.

2-Amino-7,7-dimethyl-5-oxo-4-phenyl-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (6): Yield: 85% m.p 227-229 °C. IR (KBr): 3395, 3326, 2199, 1682 cm-1. Elemental analysis. Found, %: C 73.52; H 6.28; N 9.36, C18H18N2O2, Calculated, %: C 73.45; H 6.16; N 9.52.

2-Amino-7-hydroxy-4-phenyl-4H-chromene-3-carbonitrile (7): Yield: 78%, m.p 234-235 °C. IR (KBr): 3499, 3427, 3331, 2193 cm-1. Elemental analysis. Found, %: C 72.48; H 4.61; N 10.7. C16H12N2O2, Calculated, %: C 72.72; H 4.58; N 10.60.

3-Amino-1-phenyl-1H-benzo[f]chromene-2-carbonitrile (8): Yield: 80%, m.p 279-280 °C. IR (KBr): 3435, 3338, 2183 cm-1. Elemental analysis. Found. %: C 80.27; H 4.50; N 9.74. Calculated, %: C20H14N2O, C 80.52; H 4.73; N 9.39.

General procedure for the synthesis of compounds 9-11

To a solution of 2-amino-3-carbonitrile 6-8 (1 mmol) in 1,4-dioxane (20 mL) was added triethylorthoformate (2 mmol) and acetic anhydride (2 mmol). The reaction mixture was heated under reflux condition for 2-4 h. After the completion of the reaction, the solvent was removed and the precipitate was recrystallized from ethanol to afford the pure product 9-11.

Ethyl N-3-cyano-7,7-dimethyl-5-oxo-4-phenyl-5,6,7,8-tetrahydro-4H-chromen-2-ylformimidate (9): reaction time: 2h, Yield 85%, m.p 178-180 °C. IR (KBr): 2206, 1674 cm-1. 1H N.M.R. (CDCl3) (ppm) (J, Hz): 1.11 (3H, s, CH3), 1.19 (3H, s, CH3), 1.28 (3H, t, CH3, J=6.6), 2.25 (2H, s, CH2), 2.47 (2H, s, CH2), 4.37 (2H, q, J=6.6, CH2,) 4.54 (1H, s, Hpyran), 7.21-7.35 (5H, m, Haromatic), 8.25 (1H, s, Himine). Elemental analysis. Found. %: C 72.27; H 6.14; N 7.89. C21H22N2O, Calculated, %: C 71.98; H 6.33; N 7.99.

Ethyl N-3-cyano-7-hydroxy-4-phenyl-4H-chromen-2-ylformimidate (10): reaction time: 3h, Yield 80%, m.p 166-168 °C. IR (KBr): 3110, 2224 cm-1. 1H N.M.R. (CDCl3) (ppm) (J, Hz): 1.34 (3H, t, J=5.6, CH3,), 4.39 (2H, q, J=5.6, CH2,), 4.83 (1H, s, Hpyran), 6.79-7.37 (8H, m, Haromatic and 1H, OH), 8.39 (1H, s, Himine). 13C N.M.R. (CDCl3) (ppm): 21.1, 42.5, 64.2, 81.2, 110.2, 119.4, 119.7, 127.3, 127.7, 127.9, 128.1, 128.2, 129.0, 143.3, 157.0, 159.6, 169.1. Elemental analysis. Found, %: C 71.01; H 5.21; N 8.51. C19H16N2O3, Calculated, %: C 71.24; H 5.03; N 8.74.

Ethyl N-2-cyano-1-phenyl-1H-benzo[f]chromen-3-ylformimidate (11): reaction time: 4 h, Yield 75%, m.p 224-226 °C. IR (KBr): 2224 cm-1. 1H N.M.R. (CDCl3) (ppm) (J, Hz): 1.35 (3H, t, J=7.1, CH3), 4.40 (2H, q, J=7.1, CH2,), 5.30 (1H, s, Hpyran), 7.21-7.86 (11H, m, Haromatic), 8.45 (1H, s, Himine). 13C N.M.R. (CDCl3) (ppm): 13.9, 40.8, 64.2, 82.2, 113.9, 116.8, 118.3, 123.7, 125.2, 127.4, 127.7, 128.6, 129.1, 129.9, 130.7, 131.5, 143.1, 147.6, 156.6, 159.5. 168.2. Elemental analysis. Found. %: C 77.76; H 5.02; N 9.021. C23H18N2O2, Calculated, %: C 77.95; H 5.12; N 9.03.

General procedure for the synthesis of compounds 12-20

A mixture of imine 9-11 (1 mmol) and ammonia or primary amine (1 mmol) in ethanol or 1,4-dioxane (15 mL) was refluxed for the indicated time (Table 1). After completion of the reaction, the solid material was separated and recrystallized from ethanol to give compounds 12-20.

4-Imino-8,8-dimethyl-5-phenyl-5,7,8,9-tetrahydro-3H-chromeno[2,3-d]pyrimidin- 6(4H)-one (12): IR (KBr): 3308-3464, 1691 cm-1. 1H N.M.R. (DMSO-d6) (ppm) (J, Hz): 0.90-1.10 (6H, s, 2CH3), 2.14 (2H, s, CH2), 2.35 (2H, s, CH2), 5.58 (1H, s, Hpyran), 6.90-7.31 (6H, m, Haromatic), 7.81 (1H, s, NH), 8.07 (1H, s, HIimine), 11.61 (1H, s, NH). 13C N.M.R. (DMSO-d6) (ppm): 26.9, 28.5, 43.6, 50.5, 56.5, 127.0, 127.9, 128.5, 140.9, 143.5, 147.7, 156.7, 163.1, 164.4, 165.1, 193.8. Elemental analysis. Found. %: C 71.27; H 5.70; N 13.28. C19H19N3O2, Calculated, %: C 71.01; H 5.96; N 13.08.

4-Imino-8,8-dimethyl-3-(3-nitrophenyl)-5-phenyl-5,7,8,9-tetrahydro-3H-chromeno[2,3-d]pyrimidin-6(4H)-one (13): IR (KBr): 3421, 1684, 1645 cm-1. 1H N.M.R. (DMSO-d6) (ppm) (J, Hz): 1.00 (3H, s, CH3), 1.08 (3H, s, CH3), 2.13 (2H, s, CH2), 2.64 (2H, s, CH2), 4.40 (1H, s, Hpyran), 7.21-9.00 (11H, m, Haromatic, Himine, NH). 13C N.M.R. (DMSO-d6) (ppm): 25.1, 25.4, 27.3, 29.8, 31.2, 52.6, 101.2, 123.7, 124.9, 126.1, 128.7, 129.9, 131.2, 133.7, 135.1, 139.5, 142.1, 143.9, 145.1, 148.7, 153.2, 159.9, 173.4. Elemental analysis. Found. %: C 67.62; H 4.91; N 12.50. C25H22N4O4, Calculated, %: C 67.86; H 5.01; N 12.66.

4-Imino-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol (14): IR (KBr): 3462, 3310, 3094 cm-1. 1H N.M.R. (DMSO-d6) (ppm) (J, Hz): 5.15 (1H, s, Hpyran), 6.51-7.25 (10H, m, Haromatic, NH), 8.09 (1H, s, Himine), 9.65 (1H, s, OH). 13C N.M.R. (DMSO-d6) (ppm): 37.9, 96.6, 103.5, 112.8, 115.9, 127.1, 127.7, 129.0, 130.2, 145.4, 150.5, 156.9, 157.7, 162.9, 163.1. Elemental analysis. Found, %: C 70.23; H 4.63; N 14.59. C17H13N3O2, Calculated, %: C 70.09; H 4.50; N 14.42.

3-(2-Chlorophenyl)-4-imino-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol (15): IR (KBr): 3393, 3157, 1635 cm-1. 1H N.M.R. (DMSO-d6) (ppm) (J, Hz): 5.48 (1H, s, Hpyran), 6.56-8.26 (14H, m, Haromatic, NH, Himine), 9.79 (1H, s, OH). 13C N.M.R. (DMSO-d6) (ppm): 37.7, 98.9, 103.5, 113.1, 115.3, 126.8, 127.5, 127.9, 128.6, 129.3, 129.9, 130.4, 136.2, 144.8, 150.1, 156.7, 157.8, 159.82, 159.83, 163.3. Elemental analysis. Found, %: C 68.89; H 4.21; Cl 8.61; N 10.29. C23H16ClN3O2, Calculated, %: C 68.74; H 4.01; Cl 8.82; N 10.46.

4-Imino-3-(3-nitrophenyl)-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol (16): IR (KBr): 3402, 3142, 1612 cm-1. 1H N.M.R. (DMSO-d6) (ppm) (J, Hz): 5.74 (1H, s, Hpyran), 6.60-8.05 (12H, m, Haromatic), 8.60 (1H, s, Himine), 8.95 (1H, s, NH), 9.76 (1H, s, OH). 13C N.M.R. (DMSO-d6) (ppm): 37.2, 100.4, 103.7, 107.6, 113.3, 115.3, 117.6, 120.4, 127.3, 127.5, 129.3, 130.1, 130.2, 141.2, 145.3, 148.3, 150.3, 156.5, 158.0, 159.0, 163.6. Elemental analysis. Found, %: C 66.76; H 3.84; N 13.35. C23H16N4O4, Calculated, %: C 66.99; H 3.91; N 13.59.

4-Imino-5-phenyl-3-p-tolyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol (17): IR (KBr): 3427, 3092, 1635 cm-1. 1H N.M.R. (DMSO-d6) (ppm) (J, Hz): 2.24 (3H, s, CH3), 5.63 (1H, s, Hpyran), 6.56-7.41 (12H, m, Haromatic), 8.29 (1H, s, Himine), 8.31 (1H, s, NH), 9.71 (1H, s, OH). 13C N.M.R. (DMSO-d6) (ppm): 20.9, 37.2, 99.0, 103.5, 113.1, 115.5, 122.1, 127.3, 127.6, 129.2, 129.3, 130.2, 132.7, 137.2, 145.4, 150.3, 156.6, 157.8, 159.4, 163.1. Elemental analysis. Found. %: C 75.69; H 4.91; N 11.26. C24H19N3O2, Calculated, %: C 75.57; H 5.02; N 11.02.

3-(4-Ethylphenyl)-4-imino-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol (18): IR (KBr): 3421, 3109, 1635 cm-1. 1H N.M.R. (DMSO-d6) (ppm) (J, Hz): 1.13 (3H, t, J=7.0, CH3), 2.49 (2H, q, J=7.0, CH2), 5.63 (1H, s, Hpyran), 6.03-7.42 (12H, m, Haromatic), 8.29 (1H, s, Himine), 8.35 (1H, s, NH), 9.76 (1H, s, OH). 13C N.M.R. (DMSO-d6) (ppm): 16.2, 28.0, 37.1, 99.0, 103.5, 113.1, 115.5, 122.1, 127.3, 127.5, 128.1, 129.2, 130.3, 137.3, 139.3, 145.4, 150.3, 156.6, 157.8, 159.4, 163.1. Elemental analysis. Found. %: C 75.79; H 5.41; N 10.51. C25H21N3O2, Calculated, %: C 75.93; H 5.35; N 10.63.

3-Benzyl-4-imino-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol (19): IR (KBr): 3340, 3115 cm-1. 1H N.M.R. (DMSO-d6) (ppm) (J, Hz): 4.36 (1H, s, Hbenzyl), 4.78 (1H, s, Hpyran), 6.54-7.47 (13H, m, Haromatic), 7.79 (1H, s, NH), 8.51 (1H, s, Himine), 9.32 (1H, s, OH). 13C N.M.R. (DMSO-d6) (ppm): 42.9, 64.4, 121.2, 122.8, 123.7, 134.1, 136.5, 138.2, 140.5, 142.1, 144.3, 145.7, 148.3, 150.6, 152.1, 154.7, 156.7, 158.2, 159.6, 160.4. Elemental analysis. Found, %: C 75.48; H 5.28; N 10.90. C24H19N3O2, Calculated, %: C 75.57; H 5.02; N 11.02.

12-Phenyl-10H-benzo[f]chromeno[2,3-d]pyrimidine-11(12H)-imine (20): IR (KBr): 3437, 3317, 1647 cm-1. 1H N.M.R. (DMSO-d6) (ppm) (J, Hz): 6.06 (1H, s, Hpyran), 7.08-8.24 (14H, m, Haromatic, Himine, NH). 13C N.M.R. (DMSO-d6) (ppm): 34.7, 97.6, 118.1, 123.6, 125.3, 127.1, 127.5, 128.1, 128.9, 129.1, 129.8, 131.3, 144.2, 148.3, 156.8, 162.9. Elemental analysis. Found, %: C 77.64; H 4.50; N 12.99. C21H15N3O, Calculated, %: C 77.52; H 4.65; N 12.91.

Antibacterial activities

We used the agar disk diffusion method for this purpose. Each chemically synthesized materials (5 mg) was solved in DMSO as a solvent and 100 μL of known concentration of the test compounds was introduced onto the disks (7 mm) and then allowed to dry. Then the disk was introduced onto the upper layer of the medium with the bacteria. 100 μL of solvent (DMSO) was added to another disk and implanted as a negative control on each plate along with the standard drugs. The plates were incubated overnight at 37 °C. The inhibition zones were measured and compared with the standard drugs. The results are given in Table 2. The inhibition zone numbers are the average of three times of dependent experiments.

Results and Discussion

Compounds 6-8 were synthesized according to literature (33-35) (Scheme1). The appearance of the IR absorptions bonds due to the NH2 and CN groups of synthesized compounds 6-8 clearly confirmed the formation of these compounds.

The Imines 9-11 were prepared via reaction of 6-8 with triethylorthoformate in dioxane as a solvent. The IR spectra of 9-11 revealed the absence of the amino group, which is in support of imine formation. In the 1H NMR spectra of these compounds, the appearance of triplet and quartet signals at high field is attributed to the resonance of ethoxy group protons. The resonance of imine proton at low field is also a good evidence for formation of imine structures.

Synthesis of compounds 12-20 was achieved through the reaction of 9-11 with ammonia or primary amine in ethanol or dioxane as a solvent (Scheme 2). In this reaction, when the G group is hydrogen, the reaction may produce two amino or imino tautomers. However, the NMR evidence is consistent with imino form (36), which shows two broad separate signals for two different NH groups. Yield of products after recrstallization from ethanol was in the range of 65%-93% (Table 1). The NMR spectra, as well as the elemental analysis data of these compounds are consistent with the expected structures.

Table 1

Synthesis of chromenopyrimidines 12-20

The verification of antibacterial screening data revealed that seven out of nine tested materials showed antibacterial activities against Staphylococcus aureus and Escherichia Coli bacteria (Table 2). The maximum and minimum activities against Staphylococcus aureus were related to materials No. 15 and 18, respectively and maximum and minimum activities against Escherichia Coli were related to materials No. 15 and 16, respectively.

In conclusion, we have synthesized a series of novel chromenopyrimidine derivatives in suitable yields and the biological activity of these materials was also investigated.

Table 2

Bacterial inhibition zone around disks containing samples

Escherichia Coli (mm)Staphylococcus aureus (mm)Compound
15 ± 0.2 mm23 ± 0.2 mm12
10 ± 0.2 mm20 ± 0.2 mm13
13 ± 0.1 mm22 ± 0.2 mm14
18 ± 0.2 mm25 ± 0.1 mm 15
9 ± 0.1 mm21 ± 0.3 mm16
10±0.1 mm--17
17 ± 0.1 mm18 ± 0.3 mm18
--24 ± 0.2 mm19
14 ± 0.2 mm--20
----DMSO
Gentamicin12 mmGentamicin19 mm Standard drugs

Acknowledgements

References

  • 1.

    Lagoja I M. Pyrimidine as constituent of natural biologically active compounds. Chem. Biochem. 2005;2:1-50.

  • 2.

    Hurst EW, Hull RTJ. Two new synthetic substances active against viruses of the psittacosis-lymphogranulomatrachoma group. Med. Pharm. Chem. 1961;3:215-229.

  • 3.

    Machon Z, Cieplik J. Synthesis of furo[3,4-d]pyrimidine derivatives via reaction of 4-methylpyrimidine-5-carboxylic acids with thionyl chloride. Synt. 1986;2:142-144.

  • 4.

    Machon Z, Cieplik J. Synthesis and antineoplastic effects of furo[3,4-d]pyrimidine derivatives. J. Pharmacol. Pharm. 1988;40:201-208.

  • 5.

    Mohamed NR, El-Saidi MM, Ali YM, Elnagdi MH. Utility of 6-amino-2-thiouracil as a precursor for the synthesis of bioactive pyrimidine derivatives. Bioorg. Med. Chem. 2007;15:6227-6235. [PubMed ID: 17600721].

  • 6.

    Cieplik J, Pluta J, Meler G. Synthesis and biological investigations of pyrimidine derivatives. Arch. Pharm. 1997;330:237-241.

  • 7.

    Habib N S, Soliman R, El-Tombary A A, El-Hawash S A, Shaaban O G. Synthesis of thiazolo[4,5-d]pyrimidine derivatives as potential antimicrobial agents. Arch. Pharmacal. Res. 2007;30:1511-1520.

  • 8.

    Cieplik J, Pluta J, Gubrynowicz O. Synthesis and antibacterial activity of new sulphonamides of pyrimidine. Sci. Pharm. 2000;68:333-341.

  • 9.

    Cieplik J, Raginia M, Pluta J, Gubrynowicz O, Bryndal I, Lis T. Synthesis and antibacterial properties of 1,2,3-aryl-1,2,3,4-tetrahydropyrimido[4,5-d]pyrimidine derivatives. Acta Pol. Pharm. Drug Res. 2008;65:427-434.

  • 10.

    Pecorari P, Rinaldi M, Costantino L, Provvisionato A, Cermelli C, Portolani M. Synthesis and biological activity of pyrimido[2,1-b][1,3]thiazine, [1,3]thiazino[3,2-a]purine and [1,2,3]triazolo[4,5-d][1,3]thiazino[3,2-a]pyrimidine derivatives and thiazole analogues. Farmaco. 1991;46:899-911. [PubMed ID: 1793474].

  • 11.

    Al-Thebeiti MS. Synthesis of some new derivatives of thiazolo[3,2-a] pyrimidine-3,5,7(2H)-trione of potential biological activity. Boll. Chim. Farm. 2001;140:221-223. [PubMed ID: 11570216].

  • 12.

    Tozkoparan B, Ertan M, Kelicen P, Demirdamar R. Synthesis and anti-inflammatory activities of some thiazolo[3,2-a]pyrimidine derivatives. Farmaco. 1999;54:588-593. [PubMed ID: 10555260].

  • 13.

    El-Gaby MSA, Abdel-Hamide SG, Ghorab MM, El-Sayed SM. Synthesis and anticancer activity invitro of some new pyrimidines. Acta Pharm. 1999;49:149-158.

  • 14.

    Dave CG, Shah DR, Shah GK, Pandya PS, Dave KC, Patel VJ. Pyridopyrimidines part III Synthesis and analgesic activity of 4-aminopyrido[2,3-d]pyrimidines. Indian J. Pharm. Sci. 1986;48:75-77.

  • 15.

    Stulik K, Pacakova V. High performance liquid chromatography of biologically important pyrimidine derivatives with ultraviolet-voltametric-polarographic detection. J. Chromatogr. 1983;1:77-86. [PubMed ID: 6853658].

  • 16.

    Dave CG, Shah PR, Desai VB, Srinivasan S. Synthesis and biological activity of some pyridylthioureas and pyridopyrimidinethiones. Indian J. Pharm. Sci. 1982;44:83-85.

  • 17.

    Shigeta S, Mori S, Watanabe F, Takahashi K, Nagata T, Koike N, Wakayama T, Saneyoshi M. Synthesis and antiherpes virus activities of 5-alkyl-2-thiopyrimidine nucleoside analogues. Antivir. Chem. Chemother. 2002;13:67-82. [PubMed ID: 12238531].

  • 18.

    Mobinikhaledi A, Kalhor M. Synthesis and biological activity of some oxo- and thioxopyrimidines. Int. J. Drug Dev. Res. 2010;2:268-272.

  • 19.

    Taylor E C, Patel H H. Synthesis of pyrazolo [3,4- d]pyrimidine analogues of the potent agent N-{4-[2- (2-amino-4[3H]-oxo-7H-pyrrolo[2,3-d]pyrimidin- 5-yl)ethyl]benzoyl}-L-glutamic acid (LY231514). Tetrahedron. 1992;48:8089-8100.

  • 20.

    Hynes JB, Greatz RF, Ashton WT. Potential Purine Antagonists I. Synthesis of some bis(2,4- diaminopyrimidines) and bis(2,4-diaminoquinazolines) as potential antimalarial agents. J. Med. Chem. 1972;15:1332-1333. [PubMed ID: 4629015].

  • 21.

    Robins R K. Potential purine antagonists I. Synthesis of some 4,6-substituted pyrazolo[3,4-d]pyrimidines. J. Am. Chem. Soc. 1956;78:784-790.

  • 22.

    White FR. 4-Aminopyrazolo[3,4-d]pyrimidine and three derivatives. Cancer Chemother. Rep. 1959;3:26-36.

  • 23.

    Nekooeian AA, Khalili A, Javidnia K, Mehdipour AR, Miri R. Antihypertensive effects of some new nitroxyalkyl 1,4-dihydropyridines derivatives in rat model of two-kidney, one-clip hypertension. Iran. J. Pharm. Res. 2009;8:193-199.

  • 24.

    Jianga N, Denga X, Lib F, Quana Z. Synthesis of novel 7-substituted-5-phenyl-[1,2,4]triazolo[1,5-a] pyrimidines with anticonvulsant activity. Iran. J. Pharm. Res. 2012;11:799-806. [PubMed ID: 24250507].

  • 25.

    Sasada T, Kobayashi F, Sakai N, Konakahara T. An unprecedented approach to 4,5-disubstituted pyrimidine derivatives by a ZnCl2-catalyzed three-component coupling reaction. Org. Lett. 2009;11:2161-2164. [PubMed ID: 19371078].

  • 26.

    Munawar MA, Azad M, Siddiqui HL, Nasim FH. Synthesis and antimicrobial studies of some quinolinylpyrimidine derivatives. J. Chin. Chem. Soc. 2008;55:394-400.

  • 27.

    Abd El-Fattah O, Hassan Abbas EM, Ahmed Mohamed N, Abd-Elmoez SI. Synthesis and evaluation of some tetrahydropyrimidine derivatives as antimicrobial. Aust. J. Basic Appl. Sci. 2010;4:27-36.

  • 28.

    Khalafi Nezhad A, Zare A, Parhami A, Soltani Rad MN. Practical synthesis of some novel unsymmetrical 1,3-dialkyl pyrimidine derivatives at room temperature. Arkivoc. 2006;12:161-172.

  • 29.

    Foroughifar N, Mobinikhaledi A. Synthesis and antibacterial activities of novel pyrimidines derived from 2-oxo(or thioxo)-4-phenyl-5-carbethoxy-6- methyl-1,2,3,4-tetrahydropyrimidine. Asian J. Chem. 2002;14:614-618.

  • 30.

    Foroughifar N, Mobinikhaledi A, Fathinejad H. Microwave-assisted synthesis of some pyrimidine derivatives using polyphosphate ester (PPE) in ceramic bath. Phosphorus, Sulfur Silicon Relat. Elem. 2003;178:1241-1246.

  • 31.

    Foroughifar N, Mobinikhaledi A, Fathinejad H. Synthesis of some Biginelli compounds in solvent medium using a photochemistry method. Phosphorus, Sulfur Silicon Relat. Elem. 2003;178:495-500.

  • 32.

    Foroughifar N, Mobinikhaledi A, Karimi G, Foroughifar N. One-pot synthesis of tetrahydropyrimidines catalyzed by zeolite. Synth. React. Inorg. Met-Org. Chem. 2007;37:279-282.

  • 33.

    Tahmassebi D, Bryson JA, Binz SI. 1,4-Diazabicyclo[2 2.2]octane as an efficient catalyst for a clean, one-pot synthesis of Tetrahydrobenzo[b] pyran derivatives via multicomponent reaction in aqueous media. Synth. Commun. 2011;41:2701-2711.

  • 34.

    Shestopalov AM, Emelianova YM, Nesterov VN. One-step synthesis of substituted 2-amino-4H-chromenes and 2-amino-4H-benzo[f]chromenes Molecular and crystal structure of 2-amino-3-cyano- 6-hydroxy-4-phenyl-4H-benzo[f]chromene. Russ. Chem. Bull. 2002;51:2238-2243.

  • 35.

    Heravi MM, Baghernejad B, Oskooie HA. A novel and efficient catalyst to one-pot synthesis of 2-amino- 4H-chromenes by methanesulfonic acid. J. Chin. Chem. Soc. 2008;55:659-662.

  • 36.

    Kitamura T, Hikita A, Ishikawa H, Fujimoto A. Spectrochimica. Acta Part A. 2005;62:1157-1164.